Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) from a sell rating to a hold rating in a research note issued to investors on Saturday.

Several other equities research analysts have also weighed in on AMLX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Monday, December 29th. HC Wainwright lifted their price target on shares of Amylyx Pharmaceuticals from $28.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday. Bank of America boosted their price target on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Finally, Stifel Nicolaus assumed coverage on shares of Amylyx Pharmaceuticals in a research note on Tuesday, March 3rd. They set a “buy” rating and a $21.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.56.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock opened at $13.85 on Friday. The stock’s fifty day simple moving average is $13.94 and its 200 day simple moving average is $13.25. Amylyx Pharmaceuticals has a one year low of $3.11 and a one year high of $17.49. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -8.94 and a beta of -0.31.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.01. On average, research analysts anticipate that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current year.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, Director Karen Firestone bought 8,100 shares of the stock in a transaction dated Tuesday, December 23rd. The stock was bought at an average cost of $12.45 per share, for a total transaction of $100,845.00. Following the completion of the purchase, the director owned 63,100 shares in the company, valued at $785,595. This represents a 14.73% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James M. Frates sold 3,326 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $11.11, for a total transaction of $36,951.86. Following the transaction, the chief financial officer owned 177,104 shares in the company, valued at approximately $1,967,625.44. This trade represents a 1.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 151,203 shares of company stock worth $2,028,385 over the last ninety days. Company insiders own 12.30% of the company’s stock.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Meeder Asset Management Inc. bought a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter valued at approximately $25,000. California State Teachers Retirement System bought a new position in Amylyx Pharmaceuticals in the 2nd quarter worth approximately $28,000. Ameritas Investment Partners Inc. bought a new position in Amylyx Pharmaceuticals in the 2nd quarter worth approximately $45,000. Caitong International Asset Management Co. Ltd lifted its holdings in Amylyx Pharmaceuticals by 954.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock worth $47,000 after buying an additional 3,493 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after buying an additional 5,904 shares in the last quarter. 95.84% of the stock is owned by institutional investors.

Trending Headlines about Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised near-term quarterly EPS forecasts (now -$0.34 per quarter in 2026 vs prior deeper losses) and materially boosted multi?year outlook (FY2029 and FY2030 upgrades) while maintaining a “Buy” rating and a $34 price objective — a clear vote of confidence on longer?term upside.
• Positive Sentiment: Avexitide remains the company’s key near?term catalyst: Phase 3 LUCIDITY topline data due Q3 2026; management is viewed as well?funded (reported cash runway cited ~ $317M into 2028), which supports commercialization planning if results are positive. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
• Positive Sentiment: New coverage initiated by Stifel Nicolaus can increase visibility and institutional interest, a constructive development for liquidity and analyst debate. Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated at Stifel Nicolaus
• Neutral Sentiment: Q4 2025 earnings call highlighted strategic advances and the company slightly beat EPS expectations (reported -$0.30 vs -$0.31 consensus), but near?term profitability remains a multi?quarter issue. Amylyx Pharmaceuticals Inc (AMLX) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Short?interest reports in the filings provided show zero or nonsensical values (likely reporting artifacts) and so offer no clear signal on current positioning.
• Negative Sentiment: Management discontinued development of AMX0035 for progressive supranuclear palsy (PSP), narrowing the near?term pipeline and prompting at least one downgrade (from “Strong Buy” to “Buy”); loss of a program can reduce optionality and may weigh on sentiment until avexitide data arrives. Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.